Report cover image

Targeted SSTR Radionuclide Drug Conjugates Industry Research Report 2025

Publisher APO Research, Inc.
Published Jul 06, 2025
Length 122 Pages
SKU # APRC20261254

Description

Summary

According to APO Research, the global Targeted SSTR Radionuclide Drug Conjugates market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Targeted SSTR Radionuclide Drug Conjugates is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Targeted SSTR Radionuclide Drug Conjugates is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Targeted SSTR Radionuclide Drug Conjugates is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Targeted SSTR Radionuclide Drug Conjugates include Curium Pharma, ITM Radiopharma, RadioMedix, Novartis and Grand Pharmaceutical, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Targeted SSTR Radionuclide Drug Conjugates, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Targeted SSTR Radionuclide Drug Conjugates.

The report will help the Targeted SSTR Radionuclide Drug Conjugates manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.



The Targeted SSTR Radionuclide Drug Conjugates market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Targeted SSTR Radionuclide Drug Conjugates market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.

Targeted SSTR Radionuclide Drug Conjugates Segment by Company

Curium Pharma
ITM Radiopharma
RadioMedix
Novartis
Grand Pharmaceutical
Targeted SSTR Radionuclide Drug Conjugates Segment by Type

Diagnostic
Therapeutic
Targeted SSTR Radionuclide Drug Conjugates Segment by Application

Hospital
Specialist Clinic
Other
Targeted SSTR Radionuclide Drug Conjugates Segment by Region


North America
United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East & Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Targeted SSTR Radionuclide Drug Conjugates market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Targeted SSTR Radionuclide Drug Conjugates and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Targeted SSTR Radionuclide Drug Conjugates.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Targeted SSTR Radionuclide Drug Conjugates manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Targeted SSTR Radionuclide Drug Conjugates by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Targeted SSTR Radionuclide Drug Conjugates in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.

Table of Contents

122 Pages
1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Market Size (2020-2031)
2.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales (2020-2031)
2.2.3 Global Targeted SSTR Radionuclide Drug Conjugates Market Average Price (2020-2031)
2.3 Targeted SSTR Radionuclide Drug Conjugates by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Diagnostic
2.3.3 Therapeutic
2.4 Targeted SSTR Radionuclide Drug Conjugates by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Hospital
2.4.3 Specialist Clinic
2.4.4 Other
3 Market Competitive Landscape by Manufacturers
3.1 Global Targeted SSTR Radionuclide Drug Conjugates Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales (K Units) of Manufacturers (2020-2025)
3.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue of Manufacturers (2020-2025)
3.4 Global Targeted SSTR Radionuclide Drug Conjugates Average Price by Manufacturers (2020-2025)
3.5 Global Targeted SSTR Radionuclide Drug Conjugates Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Targeted SSTR Radionuclide Drug Conjugates, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Targeted SSTR Radionuclide Drug Conjugates, Product Type & Application
3.8 Global Manufacturers of Targeted SSTR Radionuclide Drug Conjugates, Established Date
3.9 Global Targeted SSTR Radionuclide Drug Conjugates Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Curium Pharma
4.1.1 Curium Pharma Company Information
4.1.2 Curium Pharma Business Overview
4.1.3 Curium Pharma Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Curium Pharma Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
4.1.5 Curium Pharma Recent Developments
4.2 ITM Radiopharma
4.2.1 ITM Radiopharma Company Information
4.2.2 ITM Radiopharma Business Overview
4.2.3 ITM Radiopharma Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
4.2.4 ITM Radiopharma Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
4.2.5 ITM Radiopharma Recent Developments
4.3 RadioMedix
4.3.1 RadioMedix Company Information
4.3.2 RadioMedix Business Overview
4.3.3 RadioMedix Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
4.3.4 RadioMedix Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
4.3.5 RadioMedix Recent Developments
4.4 Novartis
4.4.1 Novartis Company Information
4.4.2 Novartis Business Overview
4.4.3 Novartis Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
4.4.4 Novartis Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
4.4.5 Novartis Recent Developments
4.5 Grand Pharmaceutical
4.5.1 Grand Pharmaceutical Company Information
4.5.2 Grand Pharmaceutical Business Overview
4.5.3 Grand Pharmaceutical Targeted SSTR Radionuclide Drug Conjugates Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Grand Pharmaceutical Targeted SSTR Radionuclide Drug Conjugates Product Portfolio
4.5.5 Grand Pharmaceutical Recent Developments
5 Global Targeted SSTR Radionuclide Drug Conjugates Market Scenario by Region
5.1 Global Targeted SSTR Radionuclide Drug Conjugates Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region: 2020-2031
5.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region: 2020-2025
5.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Region: 2026-2031
5.3 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region: 2020-2031
5.3.1 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region: 2020-2025
5.3.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Region: 2026-2031
5.4 North America Targeted SSTR Radionuclide Drug Conjugates Market Facts & Figures by Country
5.4.1 North America Targeted SSTR Radionuclide Drug Conjugates Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2020-2031)
5.4.3 North America Targeted SSTR Radionuclide Drug Conjugates Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Targeted SSTR Radionuclide Drug Conjugates Market Facts & Figures by Country
5.5.1 Europe Targeted SSTR Radionuclide Drug Conjugates Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2020-2031)
5.5.3 Europe Targeted SSTR Radionuclide Drug Conjugates Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Market Facts & Figures by Country
5.6.1 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2020-2031)
5.6.3 Asia Pacific Targeted SSTR Radionuclide Drug Conjugates Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Targeted SSTR Radionuclide Drug Conjugates Market Facts & Figures by Country
5.7.1 South America Targeted SSTR Radionuclide Drug Conjugates Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2020-2031)
5.7.3 South America Targeted SSTR Radionuclide Drug Conjugates Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Market Facts & Figures by Country
5.8.1 Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Sales by Country (2020-2031)
5.8.3 Middle East and Africa Targeted SSTR Radionuclide Drug Conjugates Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2020-2031)
6.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2020-2031) & (K Units)
6.1.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Type (2020-2031)
6.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Type (2020-2031)
6.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Type (2020-2031)
6.3 Global Targeted SSTR Radionuclide Drug Conjugates Price by Type (2020-2031)
7 Segment by Application
7.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2020-2031)
7.1.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2020-2031) & (K Units)
7.1.2 Global Targeted SSTR Radionuclide Drug Conjugates Sales Market Share by Application (2020-2031)
7.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue by Application (2020-2031)
7.2.1 Global Targeted SSTR Radionuclide Drug Conjugates Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Targeted SSTR Radionuclide Drug Conjugates Revenue Market Share by Application (2020-2031)
7.3 Global Targeted SSTR Radionuclide Drug Conjugates Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Targeted SSTR Radionuclide Drug Conjugates Value Chain Analysis
8.1.1 Targeted SSTR Radionuclide Drug Conjugates Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Targeted SSTR Radionuclide Drug Conjugates Production Mode & Process
8.2 Targeted SSTR Radionuclide Drug Conjugates Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Targeted SSTR Radionuclide Drug Conjugates Distributors
8.2.3 Targeted SSTR Radionuclide Drug Conjugates Customers
9 Global Targeted SSTR Radionuclide Drug Conjugates Analyzing Market Dynamics
9.1 Targeted SSTR Radionuclide Drug Conjugates Industry Trends
9.2 Targeted SSTR Radionuclide Drug Conjugates Industry Drivers
9.3 Targeted SSTR Radionuclide Drug Conjugates Industry Opportunities and Challenges
9.4 Targeted SSTR Radionuclide Drug Conjugates Industry Restraints
10 Report Conclusion
11 Disclaimer
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.